FindMyKOL
Clinical trialNCT00362570CompletedPhase 2Interventional

Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma

NCT00362570 is a phase 2 interventional trial sponsored by Ohio State University Comprehensive Cancer Center. As of 21 Nov 2026, it is completed. It studies Temozolomide in Anaplastic Oligodendroglioma and Oligoastrocytoma, Mixed. The registry lists an enrollment of 1 participant at 1 site in 1 country. The registry lists a start date of 31 May 2005 and a primary completion date of 30 Apr 2007.

SponsorOhio State University Comprehensive Cancer Center →Enrollment1Anaplastic OligodendrogliomaOligoastrocytoma, Mixed
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00362570
FieldValue
Registry IDNCT00362570
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorOhio State University Comprehensive Cancer Center
Enrollment1
Registered sites1
Countries1
ConditionsAnaplastic Oligodendroglioma and Oligoastrocytoma, Mixed
DrugsTemozolomide
Start31 May 2005
Primary completion30 Apr 2007
Study completion31 Mar 2011
Last update posted30 Nov 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Rationale: Standard therapy for anaplastic oligodendrogliomas and mixed oligoastrocytomas includes radiation and chemotherapy. However, due to the potential long-term central nervous system toxicity from radiation, researchers speculate that it may be better to reserve radiation therapy for progressive disease. In addition, some patients with anaplastic oligodendroglioma and mixed oligoastrocytoma have unusually chemosensitive tumors. Previous research indicates that brain tumor patients with a deletion of the 1p chromosome have a higher response to the chemotherapy drug temozolomide.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Ohio, United States1 site
  • Ohio State University

    Columbus

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhio: 1 siteOH1PennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00362570

Each answer restates registry values shown on this page.

What is NCT00362570?

NCT00362570 is a phase 2 interventional trial sponsored by Ohio State University Comprehensive Cancer Center. It studies Temozolomide in Anaplastic Oligodendroglioma and Oligoastrocytoma, Mixed.

Who leads NCT00362570?

The registry names Herbert Newton, MD (principal investigator, Ohio State University) as the overall official.

Where does NCT00362570 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00362570 study?

The registered drug and biological interventions are Temozolomide.

When did NCT00362570 end?

The registry lists a primary completion date of 30 Apr 2007 and a study completion date of 31 Mar 2011. The sponsor last updated the record on 30 Nov 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.